![]() |
市場調查報告書
商品編碼
2080373
磁振造影造影 (MRI) 市場:2026-2032 年全球市場預測(按產品類型、組件、磁場強度、磁鐵類型、線圈類型、應用和最終用戶分類)Magnetic Resonance Imaging Market by Product Type, Component, Field Strength, Magnet Type, Coil Type, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,磁振造影(MRI) 市場將成長至 96.9 億美元,複合年成長率為 5.91%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 64.8億美元 |
| 預計年份:2026年 | 68.3億美元 |
| 預測年份:2032年 | 96.9億美元 |
| 複合年成長率 (%) | 5.91% |
磁振造影(MRI)仍然是最重要的影像學技術之一,因為它無需使用電離輻射即可實現軟組織的高對比度可視化。神經系統疾病、癌症、心血管疾病、肌肉骨骼損傷以及需要反覆影像檢查的慢性疾病帶來的持續負擔,推動了對MRI的需求。世界衛生組織(WHO)報告稱,全球有超過5500萬人患有失智症,國際癌症研究機構(IARC)估計,2022年將新增約2000萬例癌症病例,所有這些都凸顯了臨床上對先進影像技術的迫切需求。
磁振造影(MRI)領域正在經歷一場變革,採購模式正從以硬體為中心轉向以價值為導向的成像性能。醫院和影像中心正在根據生命週期成本、運轉率、技師效率、掃描速度、能耗以及支援多種臨床服務的能力來評估系統。此外,寬孔徑系統、低噪音序列、高速掃描方案以及低場或照護現場(PoC)MRI等概念的出現,正在擴大患者的就診範圍並提高他們對檢查的耐受性。
人工智慧 (AI) 正在對整個磁振造影 (MRI) 價值鏈產生累積影響,涵蓋從排班和方案選擇到影像重建、運動校正、分診、分割和報告生成支援等各個環節。 AI 驅動的重建技術能夠在保證診斷品質的前提下縮短掃描時間,這對於面臨人手不足和預約等待時間過長的放射科來說尤其重要。
由於醫療保健投資不斷增加、患者群體龐大、醫療旅遊蓬勃發展以及公立和私立醫院網路不斷擴張,亞太地區的磁振造影(MRI)市場正經歷高速成長。儘管中國、印度、日本、韓國、澳洲和東協等市場的影像能力不斷增強,但大城市醫院與農村地區醫療機構在醫療資源取得方面仍存在差距。日本擁有全球最高的MRI掃描儀普及率之一,而中國和印度則持續擴大診斷基礎設施,以滿足腫瘤科、神經科、心血管科和整形外科領域的大規模影像需求。
東協的需求正受到快速都市化、私人醫院擴張以及新加坡、泰國和馬來西亞等國醫療旅遊中心發展的影響。同時,印尼、越南和菲律賓正在發展先進的診斷成像能力。海灣合作理事會(GCC)成員國在專科醫院、腫瘤科、神經科和數位醫療計畫方面投入巨資,這支撐了對高階磁振造影系統、可靠服務和整合企業級診斷影像環境的需求。
美國憑藉著先進的臨床應用、強大的大學醫院網路、門診影像網路以及人工智慧驅動的放射學工作流程的早期應用,引領著磁振造影(MRI)領域的創新。加拿大則致力於確保公共醫療系統的可近性、縮短等待時間並進行容量規劃。同時,墨西哥和巴西正在擴展私人診斷網路和專業影像服務,以滿足不斷成長的都市區需求,並改善腫瘤、神經和肌肉骨骼影像檢查的可及性。
產業領導者應優先考慮兼具診斷品質和可衡量營運價值的磁振造影解決方案。更快的掃描流程、人工智慧驅動的重配置、遠端服務監控、直覺的介面、靈活的安裝要求以及對氦氣的減少依賴,都能直接提高吞吐量、改善患者體驗、提升檢查一致性並降低整體擁有成本。
本執行摘要是根據對公共衛生統計數據、監管資料庫、同行評審的放射學文獻、採購趨勢以及世界衛生組織 (WHO)、國際癌症研究機構 (IARC)、經濟合作暨發展組織 (OECD)、美國食品藥物管理局 (FDA) 和各國衛生機構等公共機構的政策趨勢進行的結構化審查。為避免依賴單一資訊來源的假設,我們對臨床、營運、監管和區域指標進行了交叉比對,並對研究結果檢驗。
隨著醫療系統致力於實現更早的診斷、更完善的治療方案和更安全的複查,磁振造影(MRI)依然保持著其重要的戰略地位。其發展不僅取決於掃描儀的數量,日益取決於工作流程效率、人工智慧驅動的生產力、以患者為中心的設計、永續性、互通性和服務可靠性。
The Magnetic Resonance Imaging Market is projected to grow by USD 9.69 billion at a CAGR of 5.91% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 6.48 billion |
| Estimated Year [2026] | USD 6.83 billion |
| Forecast Year [2032] | USD 9.69 billion |
| CAGR (%) | 5.91% |
Magnetic resonance imaging (MRI) remains one of the most important diagnostic imaging modalities because it delivers high-contrast visualization of soft tissue without ionizing radiation. Demand is supported by the sustained burden of neurological disorders, cancer, cardiovascular disease, musculoskeletal injuries, and chronic conditions that require repeat imaging. The World Health Organization reports more than 55 million people living with dementia globally, while the International Agency for Research on Cancer estimated around 20 million new cancer cases in 2022, reinforcing the clinical need for advanced diagnostic imaging.
The MRI market is moving beyond equipment replacement toward workflow productivity, faster scan protocols, patient comfort, helium-efficient magnet design, and AI-assisted image acquisition and interpretation. Health systems are prioritizing scanners that improve throughput, reduce rescans, support advanced applications such as functional MRI and diffusion imaging, and integrate with radiology information systems, PACS, and enterprise imaging platforms.
The MRI landscape is being reshaped by the shift from hardware-centered procurement to value-based imaging performance. Hospitals and imaging centers are evaluating systems on lifetime cost, uptime, technologist productivity, scan speed, energy use, and ability to support multiple clinical service lines. Wide-bore systems, quieter sequences, faster protocols, and low-field or point-of-care MRI concepts are also expanding patient access and improving exam tolerance.
Another transformative shift is the growing focus on sustainable MRI operations. Helium scarcity, energy consumption, and facility infrastructure costs are influencing scanner design and purchasing criteria. Vendors are responding with helium-saving magnets, improved cooling systems, advanced coils, and software that can improve signal quality without lengthening scan times. This shift is especially relevant as radiology departments balance rising imaging demand with workforce shortages, budget discipline, and expectations for lower environmental impact.
Artificial intelligence is having a cumulative impact across the MRI value chain, from scheduling and protocol selection to image reconstruction, motion correction, triage, segmentation, and reporting support. AI-based reconstruction can reduce acquisition time while preserving diagnostic quality, which is especially valuable in high-volume radiology departments facing workforce pressure and long appointment backlogs.
Regulatory activity also supports the direction of travel. The U.S. FDA has authorized hundreds of AI-enabled medical imaging devices across modalities, with radiology representing the largest share of authorized AI/ML medical devices. In MRI, the strongest near-term value lies in accelerated imaging, automated measurements, consistent image quality, workflow orchestration, and decision support rather than replacement of radiologist judgment.
Asia-Pacific is a high-growth MRI region due to rising healthcare investment, large patient populations, medical tourism, and expanding public and private hospital networks. China, India, Japan, South Korea, Australia, and ASEAN markets are strengthening imaging capacity, although access remains uneven between metropolitan hospitals and rural care settings. Japan has among the highest MRI scanner availability levels globally, while China and India continue to expand diagnostic infrastructure to address large-scale cancer, neurological, cardiovascular, and orthopedic imaging needs.
North America benefits from advanced radiology infrastructure, high utilization, strong reimbursement pathways, and early adoption of AI-enabled imaging workflows. Europe shows steady demand driven by universal healthcare systems, aging populations, cancer care pathways, and replacement of older scanners with more efficient platforms. Latin America is improving MRI availability through private diagnostics, hospital modernization, and specialty care expansion, led by Brazil and Mexico, where urban centers remain the primary hubs for advanced imaging access.
The Middle East is investing in tertiary hospitals, oncology centers, and digital health infrastructure, particularly in GCC countries where national health strategies emphasize specialized care and medical technology modernization. Africa remains underpenetrated, with MRI access concentrated in large urban hospitals; however, investments in public-private partnerships, radiology training, and lower-infrastructure imaging solutions are gradually improving diagnostic capacity for cancer, trauma, maternal health complications, and neurological disorders.
ASEAN demand is shaped by rapid urbanization, expanding private hospitals, and growing medical tourism hubs in Singapore, Thailand, and Malaysia, while Indonesia, Vietnam, and the Philippines continue to build advanced imaging capacity. The GCC is distinguished by high capital investment in specialized hospitals, oncology, neurology, and digital health programs, supporting demand for premium MRI systems, service reliability, and integrated enterprise imaging environments.
The European Union emphasizes quality, safety, sustainability, and equitable access, making energy-efficient MRI platforms, standardized imaging pathways, interoperability, and regulatory compliance increasingly important. BRICS countries represent a large-volume opportunity because of population scale, rising chronic disease burden, expanding middle-class healthcare use, and public healthcare modernization, although procurement cycles, reimbursement systems, and regional access gaps vary significantly.
G7 countries are characterized by mature installed bases, high clinical complexity, advanced research hospitals, and stronger adoption of AI-assisted reconstruction and workflow tools. NATO countries overlap heavily with advanced European and North American healthcare systems, where resilient healthcare infrastructure, cybersecurity, continuity of supply, and secure integration with hospital information systems are becoming important procurement considerations for imaging networks.
The United States leads MRI innovation through advanced clinical use, strong academic medical centers, outpatient imaging networks, and early adoption of AI-enabled radiology workflows. Canada emphasizes access, wait-time reduction, and public system capacity planning, while Mexico and Brazil are expanding private diagnostic networks and specialty imaging services to serve growing urban populations and improve access to oncology, neurology, and musculoskeletal imaging.
In Europe, the United Kingdom focuses on diagnostic capacity and National Health Service productivity, while Germany, France, Italy, and Spain maintain significant demand for replacement systems, oncology imaging, cardiac MRI, and musculoskeletal applications. Russia has a large hospital network with ongoing demand for diagnostic infrastructure, though procurement conditions can be affected by macroeconomic, regulatory, and supply-chain constraints.
China is scaling domestic imaging capacity and local manufacturing, India is expanding MRI access through private hospitals and diagnostic chains, and Japan remains one of the world's most MRI-dense markets by scanner availability. South Korea is advanced in digital hospital adoption and imaging technology, while Australia combines strong clinical standards with demand for geographically distributed diagnostic access across metropolitan, regional, and remote communities.
Industry leaders should prioritize MRI solutions that combine diagnostic quality with measurable operational value. Faster protocols, AI reconstruction, remote service monitoring, intuitive interfaces, flexible siting requirements, and lower helium dependency can directly support throughput, patient experience, exam consistency, and total cost of ownership.
Vendors and providers should align product strategy with regional realities. Premium 3T systems remain important for advanced hospitals, while cost-effective 1.5T, helium-efficient, refurbished, and lower-infrastructure models can expand access in emerging markets. Partnerships with hospitals, payers, radiology groups, academic centers, and AI developers will be essential to validate clinical outcomes, demonstrate workflow return on investment, and support responsible AI adoption.
This executive summary is built from a structured review of public healthcare statistics, regulatory databases, peer-reviewed radiology literature, procurement trends, and policy signals from recognized institutions such as WHO, IARC, OECD, FDA, and national health agencies. Insights were cross-checked across clinical, operational, regulatory, and regional indicators to avoid reliance on single-source assumptions.
The research approach emphasizes evidence-based market interpretation rather than unsupported forecasting. Demand signals were evaluated through disease burden, aging demographics, installed-base maturity, healthcare expenditure, reimbursement environment, hospital infrastructure, AI regulation, workforce availability, sustainability priorities, and regional access gaps.
MRI is positioned for sustained strategic importance as healthcare systems seek earlier diagnosis, better treatment planning, and safer repeat imaging. Growth is not defined only by scanner volume; it is increasingly shaped by workflow efficiency, AI-enabled productivity, patient-centered design, sustainability, interoperability, and service reliability.
Organizations that combine clinical credibility with flexible deployment models, data integration, secure digital workflows, and evidence-based AI adoption will be best positioned to capture MRI market opportunities across mature and emerging healthcare systems.